{
  "trial_id": "NCT01251172",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Multiple myeloma as defined below with staging based on the International Staging System",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Monoclonal plasma cells in the bone marrow \u2265 10% and/or presence of a biopsy-proven plasmacytoma",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Monoclonal protein present in the serum and/or urine (if no monoclonal protein is detected [non-secretory disease], then \u2265 30% monoclonal bone marrow plasma cells and/or biopsy-proven plasmacytoma is required)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Myeloma-related organ dysfunction (1 or more) (a variety of other types of end organ dysfunctions can occasionally occur and lead to a need for therapy; such dysfunction is sufficient to support classification as myeloma if proven to be myeloma related)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Calcium elevation in the blood (serum calcium > 10.5 mg/L or upper limit of normal)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Renal insufficiency (serum creatinine > 2mg/dL)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Anemia (hemoglobin < 10 g/dL or 2 g < normal)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Lytic bone lesions or osteoporosis (if a solitary [biopsy-proven] plasmacytoma or osteoporosis alone [without fractures] are the sole defining criteria, then > 30% plasma cells are required in the bone marrow)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patients must have measurable disease",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patients with non-secretory multiple myeloma will be eligible only if the baseline serum free light chain level is elevated (\u2265 10 mg/dL)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "For therapeutic treatment with RO4929097, patients must have peripheral blood stem cell collection of \u2265 4.0 x 10^6 cells/kg (patient's ideal body weight)",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "ECOG performance status =< 2, Karnofsky >= 60%",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Estimated life expectancy of at least 12 weeks",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "Patients with uncontrolled electrolyte abnormalities including hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia, or hypokalemia, defined as less than the lower limit of normal for the institution despite adequate electrolyte supplementation",
      "label": "triggers",
      "evidence": "quote"
    },
    {
      "criterion": "Not pregnant or nursing",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "notes": "Patient has multiple myeloma with systemic amyloidosis and is on hemodialysis for ESRD. She has a history of relapse and has received various treatments, including thalidomide and velcade.",
  "_meta": {
    "topic_id": "17",
    "trial_id": "NCT01251172",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}